ArticleHereditas2025
LINC01980 promotes the malignant progression of lung squamous carcinoma by targeting miR-204-3p.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLung squamous cell carcinoma (LUSC) is a prevalent and aggressive subtype of lung cancer. Although LINC01980 has been implicated in the development of several cancers, its specific mechanisms in LUSC remain unclear.
methodsThrough GEO database analysis, LINC01980 was identified as aberrantly expressed in LUSC. Using LncBook 2.0, we predicted a target relationship between LINC01980 and miR-204-3p. Validation was performed using dual luciferase reporter assay and RNA pull-down experiments. An analysis of LUSC clinical samples and TCGA data revealed differential expressions of LINC01980 and miR-204-3p. The expression levels of these two molecules were quantified by RT-qPCR in both patient tissues and cell lines. To measure cell proliferation, the CCK-8 assay was applied. Apoptosis was evaluated via flow cytometry, whereas cell migration and invasion were investigated using the Transwell assay. Gene knockdown experiments demonstrated that LINC01980 influences malignant phenotypes in vitro by regulating miR-204-3p.
resultsLINC01980 was abundantly expressed in LUSC tissues and cell lines and significantly enhanced malignant activities including proliferation, migration, and invasion. Furthermore, LINC01980 promotes tumor progression by suppressing miR-204-3p expression. Rescue experiments confirmed that the depletion of miR-204-3p reverses the tumor-suppressive effects caused by LINC01980 knockdown, indicating that the oncogenic function of LINC01980 is dependent on its negative regulation of miR-204-3p.
conclusionLINC01980 drives LUSC invasiveness by targeting miR-204-3p, providing new insights into its tumor-promoting role and underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.